Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 
• By Sarah Karlin-Smith
  
Some industry-FDA interactions may be smoother now that the agency has recalled some policy staff that had been subject to reduction-in-force notices. (Shutterstock)

More from US FDA

More from Pathways & Standards